Thanks to the ongoing generosity of supporters, individual, families, corporate and community groups helping raise so far over $28,000 for research. We are almost at our target of $30,000. Most people are surprised to learn that ovarian cancer is not one disease but several distinct types and subtypes. Each type differs with its prognosis, how it is spread and how it is treated. Ovarian cancer needs more research to be able to improve the low survival rate of 46%. For ovarian cancers that are rare, like Granulosa Cell Tumour – GCT and its two sub types adult Granulosa Cell Tumour […]
Australian researchers at the Hudson Institute of Medical Research are leading the way for Granulosa Cell Tumour (GCT), a rare ovarian cancer. The researchers have an opportunity to undertake enhanced DNA testing called Whole Genome Sequencing (WGS) that could hold the answers for both subtypes of GCT adult GCT and Juvenile GCT. ROC Inc. aim is to raise the $30,000 needed to help get this testing underway. With no effective treatments for this recurrent cancer, we need to act now to save lives. Every dollar you can contribute counts. Donation Page Donate now or start your own fundraiser or team.
More than 90 per cent of Australians could survive their cancer diagnosis within a decade under a comprehensive new framework developed by an alliance of expert researchers, doctors, patients, healthcare, tech and pharmaceutical leaders.
Tasha Armour CEO of Rare Ovarian Cancer Incorporated (ROC Inc.) chats to Glenda of Illawarra Women In Business (IWIB) Tasha is the 2020 IWIB Outstanding Commitment to the Community Award winner sponsored by ANZ for the work she and ROC Inc team have achieved with the world’s first and largest research for Juvenile Granulosa Cell Tumour (jGCT) a rare ovarian cancer working with the Hudson Institute of Medical Research in Melbourne, Victoria. Tasha talks about ovarian cancer and how it affects females of all ages, her daughter being diagnosed at 16 years old with jGCT and there was no research. […]
It has been an exciting start to the second half of the year for a rare ovarian cancer called Granulosa Cell Tumour (GCT). Previously GCT has received very little research to be able to have standard protocols for treatment. Consumers from around the world are helping researchers at the Hudson Institute of Medical Research in Melbourne Australia to gain more insight into this rare disease with collected data information from the GCT Survivor Sisters and tumour tissue samples from patients. Kim Eroh the founder of the Facebook group GCT Survivor Sisters in 2012 created the group to be able to […]
Rare Ovarian cancer Incorporated (ROC Inc) is raising money to fund vital ovarian cancer research. At what age can you be diagnosed with ovarian cancer? The research being conducted at the Hudson Institute of Medical Research in Melbourne, by leading International Granulosa Cell Tumour experts Dr Simon Chu and Professor Peter Fuller. Ovarian cancer can be diagnosed in females at any age from babies to menopausal women, the youngest in Australia in the research diagnosed at 11 months old. The youngest in the world in our research diagnosed at 4 months old to the eldest in our research diagnosed at 53 […]